- Anthropic’s life science plans; Novartis CEO on China deals; and moreWelcome back to Endpoints Weekly! We’re gearing up for a busy week of earnings coverage, as Moderna, AstraZeneca, GSK, Bristol Myers Squibb and more are set to report their Q2 results. In the meant…Endpoints · 1h ago↗ source
- Amgen shares new Tavneos analysis in effort to resolve FDA disputeAmgen shared a new analysis with the FDA that the company said supports keeping its controversial rare disease drug Tavneos on the market. The submission, made Thursday, includes an independent r…Endpoints · 17h ago↗ source
- Sanofi halts development of troubled immune drug in eczema<figure><div><img src="https://imgproxy.divecdn.com/FBR1IQNmU9Hqatva496Zg2G8JMHsqV0UGsf4LMARqYo/g:nowe:189:144/c:1776:1003/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS80OTY5MDc4Mzc…